Neumora Therapeutics (NASDAQ:NMRA) Stock Price Expected to Rise, Mizuho Analyst Says

Neumora Therapeutics (NASDAQ:NMRA - Free Report) had its price target hoisted by Mizuho from $4.00 to $5.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research firms have also weighed in on NMRA. Bank of America reissued an "underperform" rating and set a $1.00 price target (down from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Needham & Company LLC reissued a "buy" rating and set a $5.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.14.

Neumora Therapeutics Trading Up 8.2%

Shares of NMRA traded up $0.14 on Wednesday, reaching $1.85. The company's stock had a trading volume of 5,282,460 shares, compared to its average volume of 1,602,303. Neumora Therapeutics has a twelve month low of $0.61 and a twelve month high of $17.19. The firm has a fifty day moving average of $0.88 and a 200-day moving average of $1.28.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). As a group, research analysts predict that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. bought a new stake in Neumora Therapeutics in the fourth quarter worth about $64,000. Quantbot Technologies LP bought a new stake in Neumora Therapeutics in the fourth quarter worth about $92,000. PEAK6 LLC bought a new stake in Neumora Therapeutics in the fourth quarter worth about $117,000. EntryPoint Capital LLC purchased a new position in shares of Neumora Therapeutics in the fourth quarter worth about $135,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Neumora Therapeutics in the fourth quarter worth about $143,000. Institutional investors own 47.65% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.